On February 13, 2023, Phase I/IIa clinical trial of ST-1703 Tablets in patients with HER2-positive advanced solid tumors (including brain metastases) was successfully initiated at Jiangsu Province Hospital. The project was previously conducted in Shanghai East Hospital and achieved the expected results. The cooperation with Jiangsu Province Hospital for the clinical trial marks the comprehensive launch of the multi-center clinical trial, which aims to accelerate the clinical research process, promote the early registration and marketing of the product, and serve the patients domestically and internationally.
ST-1703 is a small molecule tyrosine kinase inhibitor independently developed through Scitech Pharma's proprietary AI drug design platform (SigmaHit®) with global intellectual property rights, and is also the second drug candidate of Scitech Pharma to enter the clinical development stage. Through SigmaHit® targeted functional design, the second generation irreversible HER2 inhibitor that highly penetrates the blood-brain barrier has been realized, which can efficiently covalently bind to the target, and is clinically proposed to be used for the treatment of HER2-positive advanced solid tumors (including brain metastases). ST-1703 strongly inhibits human epidermal growth factor receptor 2 (HER2), and can highly penetrate the blood-brain barrier, forming a high distribution in brain tissue, and thus directly inhibit the human epidermal growth factor receptor 2 (HER2), which can be highly distributed in brain tissue. ST-1703 strongly inhibits human epidermal growth factor receptor 2 (HER2) and can highly cross the blood-brain barrier and form a high distribution in the brain tissue, thus directly inhibiting the growth of primary or metastatic tumor cells expressing HER2 and inducing apoptosis of tumor cells.
Current clinical safety data show that ST-1703 has good safety and tolerability, and preliminary efficacy data indicate that subjects taking ST-1703 Tablets after failure of multiple lines of HER2 inhibitor therapy are still able to achieve disease stabilization and tumor shrinkage, which has significant potential for the treatment of HER2-positive advanced solid tumors. It is expected to make an important contribution to the treatment of HER2-positive advanced solid tumors and bring good news to patients with HER2-positive brain metastases. By conducting clinical trials with Shanghai East Hospital and Jiangsu Province Hospital, all parties have strengthened communication and cooperation to further guarantee the safety and efficacy of ST-1703.
Scitech Pharma
